Capital Counsel’s Dentsply Sirona XRAY Stock Holding History

Capital Counsel’s Portfolio XRAY Stock Details XRAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,640	Closed	-$227K	–	63
2017 Q1	$227K	Buy	+3,640	New	+$219K	0.02%	59

Other funds holding XRAY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCG

Ruane, Cunniff & Goldfarb New York $6.43B AUM 18.44% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Capital Counsel's XRAY Position: Q2 2017 in Review

Capital Counsel sold out of Dentsply Sirona (XRAY) in Q2 2017, closing a stake of 3,640 shares — an estimated $227K sold.

Capital Counsel first reported a position in XRAY in Q1 2017 and held it in 1 quarter. The position peaked at $227K in Q1 2017. 548 funds tracked by Wall St. Rank hold XRAY as of Q2 2017.

Capital Counsel reported no remaining Dentsply Sirona position as of Q2 2017 after selling out during the quarter.
Capital Counsel sold 3,640 Dentsply Sirona shares in Q2 2017, an estimated $227K.
Capital Counsel first reported a position in Dentsply Sirona in Q1 2017 and held it in 1 quarter.
Capital Counsel's Dentsply Sirona position peaked at $227K in Q1 2017.
548 funds tracked by Wall St. Rank held Dentsply Sirona as of Q2 2017.

Based on Capital Counsel's 13F filing for Q2 2017, filed 10 Aug 2017.